Biophysical properties of the clinical-stage antibody landscape

Tushar Jain,Tingwan Sun,Stéphanie Durand,Amy Hall,Nga Rewa Houston,Juergen H Nett,Beth Sharkey,Beata Bobrowicz,Isabelle Caffry,Yao Yu,Yuan Cao,Heather Lynaugh,Michael Brown,Hemanta Baruah,Laura T Gray,Eric M Krauland,Yingda Xu,Maximiliano Vásquez,K Dane Wittrup,Juergen H. Nett,Laura T. Gray,Eric M. Krauland,K. Dane Wittrup
DOI: https://doi.org/10.1073/pnas.1616408114
IF: 11.1
2017-01-17
Proceedings of the National Academy of Sciences
Abstract:Significance In addition to binding to a desired target molecule, all antibody drugs must also meet a set of criteria regarding the feasibility of their manufacture, stability in storage, and absence of off-target stickiness. This suite of characteristics is often termed “developability.” We present here a comprehensive analysis of these properties for essentially the full set of antibody drugs that have been tested in phase-2 or -3 clinical trials, or are approved by the FDA. Surprisingly, many of the drugs or candidates in this set exhibit properties that indicate significant developability risks; however, the number of such red warning flags decreases with advancement toward approval. This reference dataset should help prioritize future drug candidates for development.
multidisciplinary sciences
What problem does this paper attempt to address?